CAS: 239087-05-9; (2-Fluoro-4-(Trifluoromethyl)Phenyl)Methanamine

上下游产品

2-fluoro-4-(trifluoromethyl)benzonitrile ethyl 2-ethyl-3-[4-methoxy-3-[N-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]carbamoyl]phenyl]propionate methyl 1-{[2-fluoro-4-(trifluoromethyl)phenyl]methyl}-4-hydroxy-6-oxo-1,6-dihydro-3-pyridinecarboxylate 7-({[2-fluoro-4-(trifluoromethyl)phenyl]methyl}amino)-2,2-dimethyl-4H,5H-pyrano[4,3-d][1,3]dioxin-4.5-dione

2-氟-4-三氟甲基苯腈 反应生成2-氟-4-三氟甲基苄胺
参考文献:Fused Azabicyclic Compounds That Inhibit Vanilloid Receptor Subtype 1 (Vr1) Receptor
标题:Fused Azabicyclic Compounds That Inhibit Vanilloid Receptor Subtype 1 (Vr1) Receptor
摘要:式(i)的化合物是新颖的vr1拮抗剂,可用于治疗疼痛,炎症性热性过敏,尿失禁和膀胱过度活动.

专利信息

专利号:US-2008096868-A1
优先权日:2004-11-12
标题:1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors
发明人：SCHMIEDEBERG NIKO; FURET PASCAL; IMBACH PATRICIA; HOLZER PHILIPP
权利人:SCHMIEDEBERG NIKO; FURET PASCAL; IMBACH PATRICIA; HOLZER PHILIPP
摘要:The invention relates to 1,4-substituted pyrazolopyrimidine compounds of the formula I, n npharmaceuticals comprising a 1,4-substituted pyrazolopyrimidine compound, the use of a 1,4-substituted pyrazolopyrimidine compound in the treatment or the use thereof in the manufacture of a pharmaceutical formulation for the treatment of a disease that depends on inadequate activity of a protein kinase, methods of treatment comprising administering a 1,4-substituted pyrazolopyrimidine compound, methods for the manufacture of a novel compound of that class, and novel intermediates and partial steps for their synthesis.

专利号:US-2008096883-A1
优先权日:2004-08-11
标题 :Trifluoromethyl substituted benzamides as kinase inhibitors
发明人：CARAVATTI GIORGIO; FURET PASCAL; IMBACH PATRICIA; MARTINY-BARON GEORG; PEREZ LAWRENCE BLAS; SHENG TAO
权利人:CARAVATTI GIORGIO; FURET PASCAL; IMBACH PATRICIA; MARTINY-BARON GEORG; PEREZ LAWRENCE BLAS; SHENG TAO
摘要:The invention relates to trifluoromethyl substituted benzamide compounds of the formula (I), pharmaceuticals comprising these compounds, their use as or for the manufacture of pharmaceuticals, particularly as inhibitors of protein kinases and/or the treatment of a condition, disorder or disease state mediated by a protein kinase activity and/or a proliferative disease, methods of treatment comprising administering the compounds, especially of therapeutic and prophylactic treatment, methods for the manufacture of the compounds and novel intermediates and partial steps for their synthesis.